Discover
ATYR
aTyr Pharma, Inc.
0.59
2 x 0.43
2 x 0.76
bid
ask
-
0.01
1.17%
2 @ 04:00 PM
0.59 -0.00 (0.05%)
| Ytd | -24.67% | |
| 1y | -88.50% |
0.57
day range
0.62
0.40
52 week range
7.29
| Open | 0.60 | Prev Close | 0.60 | Low | 0.57 | High | 0.62 | Mkt Cap | 57.83M |
| Vol | 1.44M | Avg Vol | 2.57M | EPS | -0.74 | P/E | N/A | Forward P/E | -4.33 |
| Beta | 1.10 | Short Ratio | 2.66 | Inst. Own | 63.15% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-06 | 50-d Avg | 0.61 | 200-d Avg | 0.78 | 1yr Est | 21.29 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2024-11-07 | 2024-09 | -0.22 | -0.23 | -0.01 | -4.55% |
| 2024-08-13 | 2024-06 | -0.22 | -0.23 | -0.01 | -4.55% |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2024-12-10 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-12-03 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-10-29 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-10-04 | Wells Fargo | Upgrade | Overweight | |
| 2024-09-05 | Jefferies | Upgrade | Buy | |
| 2024-08-15 | HC Wainwright & Co. | Upgrade | Buy | Buy |
Profile
aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase III clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD. The company is developing ATYR0101, a fusion protein derived from a domain of aspartyl-tRNA synthetase that is in preclinical development for the treatment of fibrosis; and ATYR0750, a domain of alanyl-tRNA synthetase for the treatment of liver disorders. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILDs in Japan. aTyr Pharma, Inc. was incorporated in 2005 and is headquartered in San Diego, California.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2024-02-05 | BROADFOOT JILL MARIE | Chief Financial Officer | 20.82K | Sale |
| 2023-04-25 | CLARKE JOHN K. | Director | 19.80K | Conversion of Exercise of derivative security |
| 2024-05-29 | COUGHLIN TIMOTHY P | Director | 0.00 | Purchase |
| 2024-06-04 | DENYES NANCY | General Counsel | 22.27K | Purchase |
| 2023-04-25 | GROSS JANE A | Director | 6.00K | Conversion of Exercise of derivative security |
| 2023-04-25 | LUCAS SVETLANA | Director | 6.00K | Conversion of Exercise of derivative security |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | Federated Hermes, Inc. | 14.67M | 50.16M | 17.47% |
| 2024-09-29 | FMR, LLC | 11.37M | 38.88M | 13.54% |
| 2024-09-29 | Vanguard Group Inc | 2.99M | 10.22M | 3.56% |
| 2024-09-29 | Tikvah Management LLC | 2.46M | 8.42M | 2.93% |
| 2024-09-29 | Logos Global Management LP | 2.00M | 6.84M | 2.38% |
| 2024-09-29 | Checkpoint Capital L.P. | 1.74M | 5.94M | 2.07% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-07-30 | Federated Hermes Kaufmann Fund | 7.85M | 26.85M | 9.35% |
| 2024-07-30 | Federated Hermes Kaufmann Small Cap Fund | 6.62M | 22.64M | 7.89% |
| 2024-10-30 | Fidelity Growth Company Fund | 2.89M | 9.88M | 3.44% |
| 2024-10-30 | Fidelity Select Portfolios - Biotechnology | 2.52M | 8.63M | 3.01% |
| 2024-09-29 | Vanguard Total Stock Market Index Fund | 2.07M | 7.07M | 2.46% |
| 2024-10-30 | Fidelity Growth Company K6 Fund | 1.05M | 3.60M | 1.25% |